[Expert consensus on physician-pharmacist collaborative management of stable chronic obstructive pulmonary disease].

Chronic obstructive pulmonary disease (COPD) is a common chronic airway disease. COPD patients need lifelong treatment, and long-term standardized inhalation medication is the core of stable COPD drug therapy. But, in the process of COPD stabilization management, the use accuracy rate of inhalation device is low and compliance is poor, and in addition, chronic diseases such as ischemic heart disease, heart failure, hypertension and diabetes are common in COPD patients, and these complications often involve multiple medications, which have potential drug risks associated with drug interactions that affect patient outcomes. Based on the experience of pharmacists involved in the management of other chronic diseases, experts from Respiratory Equipment Technical Committee of China Association of Medical Equipment, jointly with Chronic Obstructive Pulmonary Disease Group of Chinese Thoracic Society and Guangdong Pharmaceutical Association, developed expert consensus on physician-pharmacist collaborative management of stable chronic obstructive pulmonary disease, aiming to improve patients' treatment compliance and satisfaction, reduce the acute attack rate, and ultimately improve the treatment level of COPD.慢性阻塞性肺疾病（慢阻肺）是常见的慢性气道疾病，患者需要终生治疗，长期规范的吸入用药是稳定期患者的治疗核心。但在慢阻肺患者稳定期的管理过程中，其吸入装置使用正确率偏低、且治疗依从性差。此外，慢阻肺患者常合并缺血性心脏病、心力衰竭、高血压、糖尿病等慢性病，而这些合并症常涉及多种药物同时使用，存在潜在药物相互作用引起的用药风险，影响患者预后。基于药师参与其他慢病管理的有关经验，中国医学装备协会呼吸病学装备技术专业委员会联合中华医学会呼吸病学分会慢性阻塞性肺疾病学组及广东省药学会邀请呼吸学科的医师和药师，根据我国相关研究成果及临床实践经验，借鉴国外医师-药师协作管理模式，通过医师和药师共同讨论制定了稳定期慢阻肺医药共管专家共识。旨在提升患者治疗依从性和满意度，降低急性发作率，最终提升慢阻肺治疗水平。.